Dr. James B Kopp, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 221 3rd St W, Bldg 1040, Randolph A F B, TX 78150 Phone: 210-652-3383 |
Dr. Leonard E. Trout Iii, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 550 C St W, Hq Afpc/dpamm, Randolph A F B, TX 78150 Phone: 210-565-0668 Fax: 210-565-2354 |
Dr. Richard Leroy Mooney, M.D. Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 221 3rd St W, Randolph A F B, TX 78150 Phone: 210-652-8544 Fax: 210-652-9836 |
Dr. Cesario Ferrer Ferrer Jr., MD, MPH Family Medicine Medicare: Medicare Enrolled Practice Location: 221 3rd St W, Randolph A F B, TX 78150 Phone: 210-652-9204 |
News Archive
Scientists from Russia and Switzerland have probed into nanostructures covering the corneas of the eyes of small fruit flies. Investigating them the team learned how to produce the safe biodegradable nanocoating with antimicrobial, anti-reflective, and self-cleaning properties in a cost-effective and eco-friendly way.
The first ever actuarial analysis of lung cancer mortality, published today in Population Health Management Journal, provides strong evidence that earlier detection could reduce the number of late stage lung cancer deaths by over 70,000 people each year in the US.
Implementation of electronic medical records (EMR) by healthcare providers and facilities remains at an all-time low. According to so many reports, the determining factor responsible for this type of low implementation of EMR is cost. As reported by USA Today, upfront costs (which include purchasing servers, computers and software) can be as high as $36,000 per physician. In addition, the learning curve for these programs is steep, increasing the amount of time a physician spends per patient. All of these are true until now.
By monitoring the behavior of a class of cells in the brains of living mice, neuroscientists at Johns Hopkins discovered that these cells remain highly dynamic in the adult brain, where they transform into cells that insulate nerve fibers and help form scars that aid in tissue repair.
Angiochem, Inc. a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier to treat brain diseases, announced today that its lead drug candidate, ANG1005, has demonstrated a favorable safety and efficacy profile in more than 100 patients with brain cancer from two separate Phase 1 /2 clinical studies in patients with progressive gliomas, including recurrent glioblastoma, and in patients with progressive brain metastases.
› Verified 4 days ago